We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

2 hedge funds and large institutions have $6.92M invested in Seelos Therapeutics, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding

Funds holding: 1 → 2 (+1)

51% more capital invested

Capital invested by funds: $4.58M → $6.92M (+$2.35M)

38% less call options, than puts

Call options by funds: $302K | Put options by funds: $490K

Holders
2
Holders Change
+1
Holders Change %
+100%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
$302K
Puts
$490K
Net Calls
-$188K
Net Calls Change
+$281K

Top Buyers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
+$2.7M

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.41M – – –
VAM
2
Visium Asset Management
New York
$2.37M +$2.7M +1 New
California Public Employees Retirement System
3
California Public Employees Retirement System
California
$560K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$271K – – –
BFA
5
BlackRock Fund Advisors
California
$258K – – –
DIA
6
Denver Investment Advisors
Colorado
$150K – – –
Northern Trust
7
Northern Trust
Illinois
$139K – – –
Bank of New York Mellon
8
Bank of New York Mellon
New York
$106K – – –
RG
9
Rathbones Group
United Kingdom
$75K – – –
Group One Trading
10
Group One Trading
Illinois
$73K – – –
HCM
11
Highlander Capital Management
New Jersey
$51.6K – – –
RCM
12
Rotella Capital Management
Washington
$50K – – –
Citadel Advisors
13
Citadel Advisors
Florida
$39K – – –
VKH
14
Virtu KCG Holdings
New York
$38K – – –
GC
15
Guggenheim Capital
Illinois
$37K – – –
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$35K – – –
Deutsche Bank
17
Deutsche Bank
Germany
$34K – – –
Goldman Sachs
18
Goldman Sachs
New York
$28K – – –
Morgan Stanley
19
Morgan Stanley
New York
$27K – – –
SM
20
Sabby Management
Florida
$27K – – –
State Street
21
State Street
Massachusetts
$25K – – –
BA
22
BlackRock Advisors
Delaware
$24K – – –
Millennium Management
23
Millennium Management
New York
$24K – – –
RC
24
Randolph Company
Ohio
$22K – – –
WA
25
WFG Advisors
Texas
$21K – – –
1
2

SEEL Hedge Fund Activity: Q1 2014 in Review

2 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q1 2014, worth a combined $6.92M — up 51% from $4.58M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new SEEL positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Visium Asset Management, opening a new position worth an estimated $2.7M. The largest seller was Tower Research Capital (TRC), cutting an estimated $5K.

  • 2 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q1 2014, up from 1 in Q4 2013.
  • Funds reported $6.92M of Seelos Therapeutics, Inc. Common Stock stock for Q1 2014, up 51% quarter-over-quarter.
  • 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q1 2014 and 0 closed out, a net change of +1 holder.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q1 2014 was Visium Asset Management, an estimated $2.7M added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q1 2014 was Tower Research Capital (TRC), an estimated $5K sold.

Based on aggregated 13F filings for Q1 2014.